CBCI COLORADO BLOOD CANCER INSTITUTE | SARAH CANNON Cancer Institute at Presbyterian/St. Luke's Medical Center | HealthONE

CBCI Research - Sponsored Protocol List
June 2022

DISEASE	STATUS	STUDY #	Phase	TITLE	INCLUSION / EXCLUSION	NCT #
Chronic GVHD	Open	BMT 29	2	Pilot Study of INCB039110 (Itacitinib) for the Treatment of Steroid Refractory Chronic Graft-Versus-Host Disease	**Inclusion:** Moderate or severe cGVHD; steroid refractory; **Exclusion:** More than 1 prior allo-HCT or DLI; currently receiving concomitant JAK inhibitor for cGVHD	NCT04200365
Auto transplant, MS	Open	BMT 38		A Multicenter Randomized Controlled Trial of Best Available Therapy versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis	**Inclusion:** Age 18-55; EDSS between 2.0 and 5.5; treatment-resistant relapsing MS **Exclusion:** Primary Progressive MS	NCT04047628
Post Transplant	Open	BMT 41	3	A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML)	**Inclusion:** Planning to undergo or have received allogenic stem cell transplant in the past 14 days; blast percentage in bone marrow before transplant < 10% **Exclusion:** History of disease progression during prior treatment with venetoclax	NCT04161885
Transplant	Open	BMT 43	3	A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 plus Standard of Care versus Placebo plus Standard of Care in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)	**Inclusion:** Hodgkin lymphoma or non-Hodgkin lymphoma; candidate for AHCT with BEAM or BeAM **Exclusion:** Prior HCT; lymphoma with CNS involvement	NCT05181540
AML	Open	AML 56	3	A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy	**Inclusion:** 2nd morphological complete remission for AML; WT1 blasts **Exclusion:** APL; planned hematopoietic stem cell transplant; CNS leukemia	NCT04229979
AML	Open	AML 58	2	SY-1425 in Combination with Venetoclax and Azacitidine in Adult Patients with RARA-positive, Previously Untreated AML Who Are Ineligible for Standard Induction Therapy	**Inclusion:** Newly diagnosed, untreated AML; bone marrow or peripheral blast count ≥20% **Exclusion:** APL; CNS leukemia	NCT04905407
AML	On Hold	AML 59	3	A Phase 3, Randomized, -Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine versus Physician's Choice of Venetoclax plus Azacitidine or Intensive Chemotherapy in Previously Untreated Patients with TP53 Mutant Acute Myeloid Leukemia	**Inclusion:** Untreated AML with at least 1 TP53 mutation; ECOG ≤ 2 **Exclusion:** Prior treatment with CD47 or SIRPα-targeting agents; APL	NCT04778397
AML	Open	AML 60	1b	A Phase 1b/2, Open-label, Global, Multicenter, Dose-Determination, Dose Expansion, Umbrella Study to Evaluate Safety, Tolerability, and Preliminary Efficacy of CC-486 (ONUREG®) in Combination Therapy in Subjects with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (HR-MDS)	**Inclusion**: R/R AML after 2 cycles of therapy or Newly diagnosed, unfit AML; WBC ≤ 25 x 109/L **Exclusion**: APL; BCR-ABL1 positive	NCT04887857
AML/MDS	Open	AML 63	1b	Phase 1b Open-Label, Dose-Escalation and Dose-Expansion Study of APVO436 In Patients with Relapsed or Refractory AML or High-Grade MDS	**Inclusion:** R/R AML or MDS with > 5% blasts in the marrow or any blasts in the peripheral blood; ECOG ≤ 2 **Exclusion:** APL; CNS disease; prior anti-CD123 therapy	NCT03647800
AML/MDS	Open	HR 63	1	A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer (ACR NK) Cell Therapy, in Subjects with Hematological Malignancies or Dysplasias.	**Inclusion:** Received at least 1 prior line of therapy for AML or MDS; ECOG ≤2 **Exclusion:** APL; CNS involvement	NCT04623944
AML	Open	HR 70	1	A Phase I, Open-Label, Multicenter Study of FT538 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma	**Inclusion:** R/R AML or MM **Exclusion:** ECOG ≥ 2; clinically significant cardiovascular disease; CNS involvement or disease	NCT04614636

CBCI COLORADO BLOOD CANCER INSTITUTE | SARAH CANNON Cancer Institute at Presbyterian/St. Luke's Medical Center | HealthONE

CBCI Research - Sponsored Protocol List
June 2022

DISEASE	STATUS	STUDY #	Phase	TITLE	INCLUSION / EXCLUSION	NCT #
MDS	Open	MDS 30	2	Single-arm, open label, phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investigator's choice (IV/SC/Oral) for patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R criteria (US multi-center) (STIMULUS MDS-US)	**Inclusion:** Not suitable for immediate myeloablative chemotherapy or transplant; ECOG ≤2 **Exclusion:** Prior exposure to TIM-3 therapy; diagnosis of AML, APL, or CMML	NCT04878432
AML/MDS	Open	MDS 31	1	A Phase 1/2 Open-Label Study of the Safety, Tolerability, and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound ELTANEXOR (KPT-8602) in Patients with Newly Diagnosed and Relapsed/Refractory Cancer Indications	**Inclusion:** MDS with 5-19% blasts, HMA refractory **Exclusion:** Impaired cardiac function or significant cardiac diseases; very low or low-1 risk MDS	NCT02649790
ALL	Open	ALL 06	1b/2	An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of Auto1, A CAR T Cell Treatment Targeting CD19, In Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia	**Inclusion:** Documentation of CD19 expression; ECOG ≤1 **Exclusion:** Burkitt's leukemia/lymphoma; history or presence of clinically relevant CNS pathology	NCT04404660
NHL, AML, MM	Open	HR 56	1a/1b	A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients with Advanced Relapsed or Refractory Lymphoma or Myeloma	**Inclusion:** R/R transfusion-independent lymphoma, newly diagnosed AML, or R/R myeloma; ECOG ≤2 **Exclusion:** Known, current CNS disease involvement or untreated brain metastases	NCT03530683
AML/MDS	Open	HR 61	1	A Phase 1 Study of SEA-CD70 Monotherapy or Combination with Azacitidine in Subjects with Myeloid Malignancies	**Inclusion:** At least one cytopenia (absolute neutrophil count [ANC] <1800/µL or platelet count <100,000/µL or hemoglobin [Hgb] <10 g/dL). **Exclusion**: Prior allogeneic hematopoietic stem cell transplant, for any condition	NCT04227847
Multiple Myeloma, NHL	Open	HR 68	1	A Phase I/II Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma	**Inclusion:** Relapsed or refractory multiple myeloma or relapsed or refractory NHL; received at least 2 prior lines of therapy **Exclusion:** CNS disease; peripheral neuropathy > Grade 1	NCT04756726
Lymphoma	Open	HR 69	1	A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with B-Cell Malignancies	**Inclusion:** ECOG ≤1; relapsed or refractory NHL, ALL, or iNHL; at least 2 prior lines **Exclusion:** CNS disease; concomitant malignancy	NCT05020678
MCL	Open	LYM 111	2	Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2)	**Inclusion:** 1 measurable lesion; Platelet count > 75,000/uL **Exclusion:** Seizure disorder or any autoimmune disease with CNS involvement	NCT02601313
NHL Maintenance	Open	LYM 155	2	Single Arm, Phase II Study of Acalabrutinib as Post-Autologous Blood or Marrow Transplant (BMT) Maintenance Therapy in Subjects with Mantle Cell Lymphoma	**Inclusion:** Eligible for first BMT after induction chemotherapy; archival tumor block for MRD testing **Exclusion:** Relapse or progression prior to BMT; mutations that confer resistance to a BTK inhibitor; prior malignancy	NCT04402138
iNHL, NHL	Open	LYM 166	1/2a	Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma – A First-in-Human, Open-label, Phase I/IIa Dose Escalation Trial with Dose Expansion Cohorts	**Inclusion:** FL, MZL, SLL, DLBCL, HGBCL, PMBCL, MCL, or CLL;ECOG ≤1 **Exclusion:** Prior CD37 therapy; prior allogeneic HSCT	NCT04358458
NHL	Open	LYM 168	1/ 2	A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)	**Inclusion:** Relapsed/refractory large B-cell lymphoma; at least 1 measurable lesion; at least 2 lines of prior therapies including an anthracycline and an anti-CD20 monoclonal antibody **Exclusion:** History of or current CNS involvement	NCT04416984
NHL	Open	LYM 171	`1/ 2	A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma	**Inclusion:** CD20+; relapsed or refractory following anti-CD20 monoclonal antibody **Exclusion:** CNS involvement; significant cardiac disease; eligible for curative salvage therapy with high dose therapy followed by stem cell rescue	NCT03625037

CBCI Research - Sponsored Protocol List
June 2022

DISEASE	STATUS	STUDY #	Phase	TITLE	INCLUSION / EXCLUSION	NCT #
Lymphoma	Open	LYM 184	1	A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies	**Inclusion:** R/R CLL, SLL, WM, MCL, MZL, FL or DLBCL; ECOG ≤1 **Exclusion:** CNS lymphoma in remission for less than 2 years; Richter's transformation, prolymphocytic leukemia, or blastoid lymphoma	NCT04830137
NHL	Open	LYM 194	`1/2	A Phase 1/2, Open-Label, First-in-Human, Multiple Ascending Dose Multicenter Study of MT-101 in Subjects with CD5+ Relapsed/ Refractory Peripheral T Cell Lymphoma	**Inclusion:** R/R T-cell Lymphoma with at least 2 lines of prior therapy; CD5-expressing tumor by IHC or flow cytometry **Exclusion:** CNS lymphoma; prior allogeneic transplant	NCT05138458
NHL	Open	LYM 197	`1/2	A Phase 1/2 Study of bbT369, a dual targeting CAR T cell drug product with a gene edit, in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma	**Inclusion:** R/R B-cell NHL after auto transplant or at least 2 prior lines including an anti-CD20 monoclonal antibody and an anthracycline containing chemotherapy regimen **Exclusion:** Progression within 6 weeks of prior anti-CD19 CAR T therapy; primary CNS lymphoma or history of CNS pathology	NCT05169489
NHL	Open	LYM 198	`1/2	Phase 1/2, Multicenter, First-In-Human, Dose-Escalating Study of CPO107 Administered IVI to Patients with Incurable CD20+ve NHL	**Inclusion:** CD20+ NHL; disease progression following 2 or more prior lines including a CD20 targeted therapy **Exclusion:** Prolongation of QT/QTc interval at baseline; other active cancers or treatment of invasive cancers within 3 years	NCT04853329
Multiple Myeloma Maintenance	Open	MM 109	3	A Randomized Study of Daratumumab plus Lenalidomide vs. Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive after Frontline Autologous Stem Cell Transplant	**Inclusion:** Newly diagnosed multiple myeloma with 4-8 cycles of induction and autologous stem cell transplant; archived bone marrow biopsy sample collected before induction or transplant **Exclusion:** Peripheral neuropathy or neuropathic pain Grade 2+; CNS involvement	NCT03901963
Multiple Myeloma	Open	MM 113	1	A Single-Arm, Open-Label, Phase 1 Study of the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 to Evaluate an Anti-BCMA Allogeneic CAR T Cell Therapy in Subjects With Relapsed/Refractory Multiple Myeloma	**Inclusion:** Relapsed or refractory MM after 3+ lines of therapy **Exclusion:** Known active or history of CNS involvement; prior allogeneic HCT	NCT04093596
Multiple Myeloma Maintenance	Open	MM 117	2	A Multicenter, Open-label, Single Arm, Phase II study of Daratumumab as Consolidation/Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma	**Inclusion:** Received at least 2 cycle of initial therapy for MM **Exclusion:** Prior disease progression with daratumumab; previous autologous or allogeneic transplant	NCT03346135
Multiple Myeloma	Open	MM 121	1/2	A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relapsed/Refractory Multiple Myeloma	**Inclusion:** At least 3 prior lines of therapy (including proteasome inhibitor, immune modulatory drug, and an anti-CD38 antibody) **Exclusion:** Concurrent treatment with anti-tumor necrosis factor alpha therapies	NCT04184050
Multiple Myeloma	Open	MM 127	1	A Phase 1, Multicenter Open-Label Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma	**Inclusion:** At least 3 prior lines including a proteasome inhibitor, an immunomodulatory drug and an anti-CD38 drug; ECOG ≤1 **Exclusion:** Active or history of CNS involvement; prior GPRC5D targeted therapy	NCT04674813
Multiple Myeloma	Open	MM 131	1	A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants with Multiple Myeloma	**Inclusion:** 3 or more prior lines of therapy; ECOG ≤1 **Exclusion:** Plasma cell leukemia; prior BCMA therapy	NCT04557098
Multiple Myeloma	Open	MM 135	3	(SAR650984) In Combination With Lenalidomide And Dexamethasone Versus Lenalidomide And Dexamethasone In Patients With High-Risk Smoldering	**Inclusion:** Symptomatic R/R MM; ECOG ≤2 **Exclusion:** Primary systemic amyloid light-chain amyloidosis	NCT04270409
Multiple Myeloma	Open	MM 137	1	A Phase I Study of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma	**Inclusion:** R/R MM after at least 2 prior lines; ECOG ≤2 **Exclusion:** Receiving immunosuppressive therapy; active CNS involvement	NCT05182073

CBCI COLORADO BLOOD CANCER INSTITUTE | SARAH CANNON Cancer Institute at Presbyterian/St. Luke's Medical Center | HealthONE

CBCI Research - Sponsored Protocol List
June 2022

DISEASE	STATUS	STUDY #	Phase	TITLE	INCLUSION / EXCLUSION	NCT #
Multiple Myeloma	Open	MM 138	1/2	A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-647 and ALLO-605, an Anti-BCMA Allogenic CAR T Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma	**Inclusion:** R/R MM after at least 3 prior lines; ECOG <2 **Exclusion:** History of CNS involvement; prior allogeneic stem cell transplant; other malignancy requiring treatment within past 3 years	NCT05000450
Multiple Myeloma	Pending	MM 141	EAP	An open-label, single arm multicenter Phase 2 study to evaluate the safety and efficacy of cilta-cel OOS in the adult participants (≥18 years) with multiple myeloma, within the cilta-cel labeled indication, and whose final manufactured cilta-cel OOS does not meet the commercial release specifications	**Inclusion:** Batch of cilta-cel that is nonconforming **Exclusion:** Active, uncontrolled infection	NCT05347485
Multiple Myeloma	Open	MM 142	2	Open label, multi-center, Phase 1b/2 clinical trial to evaluate the safety and efficacy of autologous CAR-BCMA T cells (CT053) in patients with relapsed and/or refractory multiple myeloma	**Inclusion:** R/R MM including treatment with a proteasome inhibitor, IMiD and daratumumab; ECOG ≤1 **Exclusion:** Prior BCMA therapy; GvHD	NCT03915184
Multiple Myeloma	Open	MM 143	1b	An Open-Label, Multicenter, Phase 1b Trial Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Patient with Relapsed or Refractory Multiple Myeloma	**Inclusion:** R/R MM with no available therapies or intolerance to established therapies; ECOG ≤1 **Exclusion:** Prior allogenic stem cell transplant; Current or past history of central nervous system disease	NCT04910568
Multiple Myeloma	Open	MM 144	2	Phase 2 Study of Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy	**Inclusion:** High-risk MM patients who complete pre-transplant induction therapy **Exclusion:** Active and uncontrolled infection	NCT04816526
Multiple Myeloma	Open	MM 145	1b	A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma	**Inclusion:** 2 or more prior lines of therapy; ECOG ≤1 **Exclusion:** Prior GPRC5D therapy; Plasma cell leukemia	NCT05050097
Multiple Myeloma	Open	MM 151	1b	A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination with Checkpoint Inhibition for the Treatment of Participants with Relapsed or Refractory Multiple Myeloma	**Inclusion:** Have measurable disease at screening as defined by at least 1 of the following: Serum M-protein level ≥0.5 g/dL; or Urine M-protein level ≥200 mg/24 hours; or Light chain multiple myeloma: Serum Ig FLC ≥10 mg/dL and abnormal serum Ig kappa lambda FLC ratio **Exclusion**: Gene-modified adoptive cell therapy (eg, CAR modified T-cells, natural killer cells) within 3 months	NCT05338775
Amyloidosis	Open	AMY 09	1/2	A Single Arm, Open-Label, Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis	**Inclusion:** Received 1-3 prior lines of therapy for AL amyloidosis; dFLC≥20 mg/L; bone marrow plasma cells <30% **Exclusion:** Presence of non-AL amyloidosis; diagnosis of multiple myeloma or smoldering multiple myeloma	NCT05199337
WM	Hold	LYM 165	1b	A Phase 1b Trial of Mavorixafor, an Oral CXCR4 Antagonist, in Combination with Ibrutinib in Patients with Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4	**Inclusion:** Confirmed MYD88 and CXCR4 mutations **Exclusion:** Previous exposure to a CXCR4 inhibitor or BTK inhibitor	NCT04274738
WM	Open	LYM 188	2	A Phase Ib /II Study of Safety, Tolerability and Efficacy of APG-2575 Alone or in Combination with Other Therapeutic Agents in Patients with Waldenström Macroglobulinemia	**Inclusion:** Symptomatic and measurable disease; ECOG ≤1 **Exclusion:** Central nervous system involvement; Concurrent malignancy	NCT04260217
COMING SOON						
AML	Pending	AML 65	2	A Phase 1/2, Multicenter, Open-label, Single Arm, Dose Escalation and Expansion Study of the combination of Gilteritinib, Venetoclax and Azacitidine in FMS-like Tyrosine Kinase 3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML)	**Inclusion**: Participant is ≥ 75 years of age and ineligible for intensive induction chemotherapy per physician's discretion with ECOG performance status 0, 1, or 2. **Exclusion**: Participant previously treated with any of the following treatments: Car-T Cell therapy	Pending

CBCI COLORADO BLOOD CANCER INSTITUTE | SARAH CANNON Cancer Institute at Presbyterian/St. Luke's Medical Center | HealthONE

CBCI Research - Sponsored Protocol List
June 2022

DISEASE	STATUS	STUDY #	Phase	TITLE	INCLUSION / EXCLUSION	NCT #
Acute GVHD	Pending	BMT 47	2	A randomized, double-blind, trial to evaluate the safety and efficacy of apraglutide in Grade II to IV (MAGIC) steroid refractory gastrointestinal (GI) acute graft versus host disease on best available therapy	**Inclusion**: Engraftment post alloSCT; treated with systemic steroids plus ruxolitinib **Exclusion**: Treatment with Janus kinase inhibitor	Pending
AML, cHL, B-ALL, HCL	Pending	HR 72	1	A Phase 1, First-in-Human, Dose Escalation and Expansion Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients with Select Relapsed or Refractory Hematologic Malignancies	**Inclusion:** Relapsed or refractory after at least 1 prior line; ECOG ≤2 **Exclusion:** APL; prior treatment with an anti-CD123 agent; CNS involvement	Pending
NHL	Pending	LYM 199	`1	A Phase 1, Open-Label, to evaluate safety, pharmacokinetics and preliminary anti-tumor activity of RO7227166 (a CD19 targeted 4-1BB ligand) in combo with obintuzumab and in combo with glofitamab following a pre-treatment dose of obintuzumab administered in participants with R/R b-cell NHL	**Inclusion:** a histologically-confirmed hematological malignancy that is expected to express CD19 and CD20; relapse after or failure to respond to at least two prior treatment regimens; Must have at least one measureable target lesion (≥ 1.5 cm) in its largest dimensionby computed tomography (CT) scan **Exclusion:** Prior allogeneic SCT; Current or past history of CNS lymphoma	NCT04077723
LYM	Pending	LYM 200	2	A Phase 2 Study to Evaluate the Safety and Efficacy of MK-1026 in Participants with Hematologic Malignancies	**Inclusion**: R/R CLL, SLL, MCL, MZL, Richter's, or Waldenstrom's; platelets >50k **Exclusion:** Active CNS disease; Prior exposure to non-covalent, reversible BTK inhibitors	Pending
BCL	Pending	LYM 201	2	A Phase 2 Open-Label, Multicenter Study Evaluating The Safety And Efficacy Of Axicabtagene-Ciloleucel Concomitant With Prophylactic Steroids In Subjects With Relapsed Or Refractory Large B-Cell Lymphoma In The Outpatient Setting (ZUMA 24)	**Inclusion:** At least 1 measurable lesion according to the Lugano Response Criteria for Malignant Lymphoma **Exclusion:** History of autologous or allogeneic stem cell transplant; prior CD19 targeted therapy	Pending
FL	Pending	LYM 202	3	A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma (ZUMA 22)	**Inclusion:** At least 1 measurable lesion; Eastern Cooperative Performance Status of 0 or 1 **Exclusion:** History of transformed FL or clinical evidence of transformed FL at the time of screening	Pending
LYM	Pending	LYM 203	1/2	An Open-Label, First in Human, Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the CTPS1 Inhibitor STP938 in Adult Subjects with Relapsed/Refractory B Cell and T-Cell Lymphomas	**Inclusion:** R/R B-Cell or T-Cell Lymphomas **Exclusion:** Subjects who have known carcinomatous meningitis or CNS involvement with lymphoma; subjects who have received prior radiation	Pending
Multiple Myeloma	Pending	MM 133	EAP	Expanded Access Protocol (EAP) for MM Patients Receiving Idecabtagene Vicleucel (Ide-cel) that is Nonconforming for Commercial Release	**Inclusion:** Batch of ide-cel that is nonconforming **Exclusion:** Significant worsening in clinical status since production of ide-cel	NCT04771078
Multiple Myeloma	Pending	MM 140	1b	A Multi-ARM, Phase Ib Study of SAR650984 (Isatuximab, an Anti-CD38 mAb) in Combination with Carfilzomib, and High-dose Carfilzomib and Dexamethasone, for the Treatment of Relapsed or Refractory Multiple Myeloma	**Inclusion:** R/R MM; ECOG ≤2 **Exclusion:** Diagnosed or treated for another malignancy within 3 years; daily requirement for corticosteroids	NCT02332850